



European Medicines Agency  
Evaluation of Medicines for Human Use

London, 6 November 2008  
Doc. Ref.: EMEA/HMPC/101620/2008

## COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

### LIST OF REFERENCES FOR ASSESSMENT OF:

**Hyperici herba**  
***Hypericum perforatum* L.**  
**(St. John's wort)**

*The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.*

Agostinis, P., Vantieghem, A., Merlevede, W., de Witte PAM. Hypericin in cancer treatment: more light on the way. *Int J Biochem. Cell Biol.* 34, 221-241. 2002

Anghelescu, IG., Kohnen, R., Szegedi, A., Klement, S., Kieser, M. Comparison of *Hypericum* extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. *Pharmacopsychiatry.* 39, 213-219. 2006

Arold, G., Donath, F., Maurer, A., Diefenbach, K., Bauer, S., Henneicke-von Zepelin, H.H., Friede, M., Roots, I. No relevant interaction with alprazolam, caffeine, tolbutamide and digoxin by treatment with a low-hyperforin St John's wort extract. *Planta Med* 71, 331-337. 2005

Auster, F., Schäfer, J. *Arzneipflanzen.* Georg Thieme Verlag, Leipzig, 1958

Axarlis, S., Mentis, A., Demetzos, C., Skaltsounis, AL., Marselos, M., Malamas, M. Antiviral *in vitro* activity of *Hypericum perforatum* extract on the Human Cytomegalovirus (HCMV). *Phytother Res* 12, 507-511. 1998

Barnes, J., Anderson, LA., Phillipson, JD. *Herbal medicines.* Second Edition. Pharmaceutical Press, London, 2002

Barnes, J., Barber, N., Wheatley, D., Williamson, EM. A pilot randomised, open, uncontrolled, clinical study of two dosages of St John's wort (*Hypericum perforatum*) herb extract (LI-160) as an aid to motivational/behavioural support in smoking cessation. *Planta Med.* 72, 378-382. 2006

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK  
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51

E-mail: [mail@emea.europa.eu](mailto:mail@emea.europa.eu) <http://www.emea.europa.eu>

© European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged

Baureithel, KK., Berger Büter, K., Engesser, A., Burkard, W., Schaffner, W. Inhibition of benzodiazepine binding *in vitro* by amentoflavone, a constituent of various species of *Hypericum*. *Phar Acta Helv* 72, 153-157. 1997

Beckman, SE., Sommi, RW., Switzer, J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. *Pharmacotherapy*. 20, 568-574. 2000

Behnke, K., Jensen, GS., Graubaum, HJ., Gruenwald, J. *Hypericum perforatum* versus fluoxetine in the treatment of mild to moderate depression. *Adv Ther*. 19, 43-52. 2002

Beijamini, V., Andreatini, R. Effects of *Hypericum perforatum* and paroxetine on rat performance in the elevated T-maze. *Pharmacol Res*. 48, 199-207. 2003

Benedi, J., Arroyo, R., Romero, C., Martin-Aragon, S., Villar, AM. Antioxidant properties and protective effects of a standardized extract of *Hypericum perforatum* on hydrogen peroxide-induced oxidative damage in PC12 cells. *Life Sci*. 75, 1263-1276. 2004

Bergmann, R., Nüßner, J., Demling, J. Behandlung leichter bis mittelschwerer Depressionen. *TW Neurol Psychiatr*. 7, 235-240. 1993

Bernd, A., Simon, S., Ramirez Bosca, A., Kippenberger, S., Diaz Alperi, J., Miquel, J., Villalba Garcia, JF., Pamies Mira, D., Kaufmann R., Phototoxic effects of *Hypericum* extract in cultures of human keratinocytes compared with those of psoralen. *Photochem Photobiol*. 69, 218-221. 1999

Biber, A., Fischer, H., Romer, A., Chatterjee, SS. Oral bioavailability of hyperforin from *Hypericum* extracts in rats and human volunteers. *Pharmacopsychiatry*. 31, Suppl 1, 36-43. 1998

Bjerksted, L., Edman, GV., Alken, RG., Mannel, M. *Hypericum* extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. *Eur Arch Psychiatry Clin Neurosci*. 255, 40-47. 2005

Bladt, S., Wagner, H. Inhibition of MAO by fractions and constituents of *Hypericum* extract. *J Geriatr Psychiatry Neurol*. 7, Suppl 1, 57-59. 1994

Böhme, H. Kommentar zum Europäischen Arzneibuch. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006

Borges, LV., do Carmo Cancino, JC., Peters, VM., Las Casas, L., de Oliveira Guerra, M. Development of pregnancy in rats treated with *Hypericum perforatum*. *Phytother Res*. 19, 885-887. 2005

Bove, GM. Acute neuropathy after exposure to sun in a patient treated with St John's wort. *Lancet* 352, 1121. 1998

Bradley, P. *British Herbal Compendium*. Vol 2. British Herbal Medicin Association, 2006

Brenner, R., Azbel, V., Madhusoodanan, S., Pawlowska, M. Comparison of an extract of *Hypericum* (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. *Clin Ther*. 22, 411-419. 2000

Butterweck, V., Brockens, T., Korte, B., Wittkowski, W., Winterhoff, H. Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. *Brain Res*. 930, 21-9. 2002

- Butterweck, V., Jurgenliemk, G., Nahrstedt, A., Winterhoff, H. Flavonoids from *Hypericum perforatum* show antidepressant activity in the forced swimming test. *Planta Med.* 66, 3-6. 2000
- Butterweck, V., Lieflander-Wulf, U., Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. *Planta Med.* 69, 189-192. 2003
- Butterweck, V., Nahrstedt, A. Was ist bekannt über Johanniskraut? *Phytochemie und Pharmakologie. Pharmazie in unserer Zeit.* 32, 212. 2003
- Butterweck, V., Petereit, F., Winterhoff, H., Nahrstedt, A. Solubilized hypericin and pseudohypericin from *Hypericum perforatum* exert antidepressant activity in the forced swimming test. *Planta Med.* 64, 291-294. 1998
- Capasso, R., Borrelli, F., Montanaro, V., Altieri, V., Capasso, F., Izzo, AA. Effects of the antidepressant St. John's wort (*Hypericum perforatum*) on rat and human vas deferens contractility. *J Urol.* 173, 2194-2197. 2005
- Calapai, G., Crupi, A., Firenzuoli, F., Interrera, G., Squadrito, F., Parisi, A., De Sarro, G., Caputi, A. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of *Hypericum perforatum*. *Pharmacopsychiatry.* 34, 45-49. 2001
- Catania, MA., Firenzuoli, F., Crupi, A., Mannucci, C., Caputi, AP., Calapai, G. *Hypericum perforatum* attenuates nicotine withdrawal signs in mice. *Psychopharmacology.* 169, 186-189. 2003
- Cervo, L., Roizo, M., Ekalle-Soppo, CB., Guiso, G., Morazzoni, P., Caccia, S. Role of hyperforin in the antidepressant-like activity of *Hypericum perforatum* extracts. *Psychopharmacology.* 164, 423-428. 2002
- Chatterjee, SS., Bhattacharya, SK., Wonnemann, M., Singer, A., Müller, WE. Hyperforin as a possible antidepressant component of *Hypericum* extracts. *Life Sci.* 63, 499-510. 1998
- Chung, DJ., Kim, HY., Park, KH., Jeong, KA., Lee, SK., Lee, YI., Hur, SE., Cho, MS., Lee, BS., Bai, SW., Kim, CM., Cho, SH., Hwang, JY., Park, JH. Black Cohosh and St. John's Wort (GYNO-Plus(R)) for Climacteric Symptoms. *Yonsei Med J.* 48, 289-294. 2007
- Commission E monographs. The Complete German Commission E Monographs. American Botanical Council, Austin, 1998
- Coskun, I., Tayfun Uzbay, I., Ozturk, N., Ozturk, Y. Attenuation of ethanol withdrawal syndrome by extract of *Hypericum perforatum* in Wistar rats. *Fundam Clin Pharmacol.* 20, 481-488. 2006
- DAC, Deutscher Arzneimittel Codex. J010 Hyperici herba. Deutscher Apotheker-Verlag, Stuttgart, 1991-1999
- De Vry, J., Maurel, S., Schreiber, R., de Beun, R., Jentsch, KR. Comparison of *Hypericum* extracts with imipramine and fluoxetine in animal models of depression and alcoholism. *Eur Neuropsychopharmacol.* 9, 461-468. 1999
- Dimpfel, W. Electropharmacogram from quercetin is similar to that of moclobemide and other antidepressant drugs. *Z Phytother.* 29, S6. 2008
- Dinamarca, MC., Cerpa, W., Garrido, J., Hancke, JL., Inestrosa, N.. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. *Mol Psychiatry.* 11, 1032-1048. 2006

- Dingermann, T., Hiller, K., Schneider, G., Zündorfer, I. Schneider Arzneidrogen. Elsevier, München, 2004
- Dugoua, JJ., Mill, E., Perri, D., Koren, G. Safety and efficacy of St. John's wort (*Hypericum*) during pregnancy and lactation. *Can J Clin Pharmacol.* 13, 268-276. 2006
- Duke, JA. Handbook of Medicinal Herbs. CRP Press LLC, 2002
- Eckert, GP., Muller, WE. Effects of hyperforin on the fluidity of brain membranes. *Pharmacopsychiatry.* 34, 22-25. 2001
- Ellis, KA., Stough, C., Vitetta, L., Heinrich, K., Nathan, PJ. An investigation into the acute nootropic effects of *Hypericum perforatum* L. (St. John's Wort) in healthy human volunteers. *Behav Pharmacol.* 12, 173-182. 2001
- El-Sherbiny, DA., Khalifa, AE., Attia, AS., Eldenshary Eel, D. *Hypericum perforatum* extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine. *Pharmacol Biochem Behav.* 76, 525-533. 2003
- Ergänzungsbuch zum Deutschen Arzneibuch (Erg.-B6). Deutscher Apotheker-Verlag, Berlin, 1941
- ESCOP Monograph. *Hyperici herba* (St. John's Wort). ESCOP Monographs Second edition. ESCOP 2003
- Fava, M., Alpert, J., Nierenberg, AA., Mischoulon, D., Otto, MW., Zajecka, J., Murck, H., Rosenbaum, JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. *J Clin Psychopharmacol.* 25, 441-447. 2005
- Findling, RL., McNamara, NK., O'Riordan, MA., Reed, MD., Demeter, CA., Branicky, LA., Blumer, JL. An open-label pilot study of St. John's wort in juvenile depression. *J Am Acad Child Adolesc Psychiatry.* 42, 908-914. 2003
- Fischer, B., Hartwich, C. Handbuch der pharmazeutischen Praxis. Verlag Julius Springer, Berlin, 1902
- Flamm, S., Kroeber, L., Seel, H. Pharmakodynamik Deutscher Heilpflanzen. Hippokrates Verlag, Stuttgart, 1940
- Flausino, OA. Jr., Zangrossi, H.Jr., Salgado, JV., Viana, MB. Effects of acute and chronic treatment with *Hypericum perforatum* L. (LI 160) on different anxiety-related responses in rats. *Pharmacol Biochem Behav.* 71, 251-257. 2002
- Fox, E., Murphy, RF., McCully, CL., Adamson, PC. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. *Cancer Chemother Pharmacol.* 47, 41-44. 2001
- Frerichs, G., Arends, G., Zörnig, H. Handbuch der pharmazeutischen Praxis. Verlag Julius Springer, Berlin, 1938
- Friede, M. Henneicke von Zepelin, HH., Freudenstein, J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. *Pharmacopsychiatry.* 34, 38-41. 2001
- Froestl, B., Steiner, B., Muller, WE. Enhancement of proteolytic processing of the beta-amyloid precursor protein by hyperforin. *Biochem Pharmacol.* 66, 2177-2184. 2003

- Gastpar, M., Singer, A., Zeller, K. Comparative efficacy and safety of a once-daily dosage of *Hypericum* extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. *Pharmacopsychiatry*. 39, 66-75. 2006
- Gastpar, M., Singer, A., Zeller, K. Efficacy and tolerability of *Hypericum* extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. *Pharmacopsychiatry*. 38, 78-86. 2005
- Genovese, T., Mazzon, E., Di Paola, R., Muia, C., Crisafulli, C., Menegazzi, M., Malleo, G., Suzuki, H., Cuzzocrea, S. *Hypericum perforatum* attenuates the development of cerulein-induced acute pancreatitis in mice. *Shock*. 25, 161-167. 2006
- Genovese, T., Mazzon, E., Menegazzi, M., Di Paola, R., Muia, C., Crisafulli, C., Bramanti, P., Suzuki, H., Cuzzocrea, S. Neuroprotection and enhanced recovery with *Hypericum perforatum* extract after experimental spinal cord injury in mice. *Shock*. 25, 608-617. 2006
- Gerlach, S. *Hypericum*. PhD Thesis, University Vienna, 2008
- Gibbons, S., Ohlendorf, B., Johnsen, I. The genus *Hypericum*-a valuable resource of anti-Staphylococcal leads. *Fitoterapia*. 73, 300-304. 2002
- Gobbi, M., Moia, M., Pirona, L., Morizzoni, P., Minnini, T. *In vitro* binding studies with two *Hypericum perforatum* extracts-hyperforin, hypericin and biapigenin-on 5-HT<sub>6</sub>, 5-HT<sub>7</sub>, GABA(A)/benzodiazepine, sigma, NPY-Y<sub>1</sub>/Y<sub>2</sub> receptors and dopamine transporters. *Pharmacopsychiatry*. 34, Suppl 1, 45-48. 2001
- Greeson, JM., Sanford, B., Monti, DA. St. John's wort (*Hypericum perforatum*): a review of the current pharmacological, toxicological, and clinical literature. *Psychopharmacology*. 153, 402-414. 2001
- Gregoretti, B., Stebel, M., Candussio, L., Crivellato, E., Bartoli, F., Decorti, G. Toxicity of *Hypericum perforatum* (St. John's wort) administered during pregnancy and lactation in rats. *Toxicol Appl Pharmacol*. 200, 201-205. 2004
- Grube, B., Grünwald, J., Walper, A., Hopfenmüller, W. Johanniskraut bei leichten temporären Verstimmungen. *Naturamed* 11, 21-27. 1996
- Grube, B., Walper, A., Wheatley, D. St. John's Wort extract: efficacy for menopausal symptoms of psychological origin. *Adv Ther*. 16, 177-186. 1999
- Gruenwald, J., Brendler, T., Jaenicke, C. PDR for Herbal Medicines. Medical Economics Company, Montvale, 1998
- Gruenwald, J., Brendler, T., Jaenicke, C. PDR for Herbal Medicines. Medical Economics Company, Montvale, 2004
- Grundmann, O., Kelber, O., Butterweck, V. Effects of St. John's wort extract and single constituents on stress-induced hyperthermia in mice. *Planta Med*. 72, 1366-1371. 2006
- Gutmann, H., Poller, B., Berger Büter, K., Pfrunder, A., Schaffner, W., Drewe, J. *Hypericum perforatum*: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? *Planta Med* 72, 685-690: 2006
- Häberlein H., Prenner L., Zeller K. Einfluss von Hyperosid und Hyperforin auf die Regulation und laterale Mobilität von beta1-adrenergen Rezeptoren an lebenden C6-Glioblastomzellen: ein postsynaptischer Ansatz zum Wirkmechanismus von Johanniskraut. *Z Phytother*. 29, 8, 2008

Hager CD-Rom, Blaschek, W., Ebel, S., Hackenthal, E., Holzgrabe, U., Keller, K., Reichluing, J., Schulz, V. HagerROM. Springer Verlag, Berlin, Heidelberg, 2006

Hager, H. Hager's Handbuch der pharmazeutischen Praxis. Verlag Julius Springer, Berlin, 1878

Hamacher, H., Wahl, MA. Selbstmedikation. 10. Ergänzungslieferung, Deutscher Apotheker Verlag Stuttgart, 2006

Hamacher, H., Wahl, MA. Selbstmedikation. 8. Ergänzungslieferung, Deutscher Apotheker Verlag Stuttgart, 2001

Hamacher, H., Wahl, MA. Selbstmedikation. 9. Ergänzungslieferung, Deutscher Apotheker Verlag Stuttgart, 2003

Hammerness, P., Basch, E., Ulbricht, C., Barrette, E.P., Foppa, I., Basch, S., Bent, S., Boon, H., Ernst, E. St. John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist. *Psychosomatics* 44(4), 271-282. 2003

Hänsel, R. Kapitel 10, Teedrogen. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1993

Hänsel, R., Keller, K., Rimpler, H., Schneider, G. Drogen E-O. Springer Verlag, Berlin, 1993

Hänsel, R., Sticher, O. Pharmakognosie – Phytopharmazie. Springer Medizin Verlag, Heidelberg, 2007

Hänsel, R., Sticher, O. Pharmakognosie – Phytopharmazie. Springer Medizin Verlag, Heidelberg, 1972

Hänsgen, KD, Vesper, J, Antidepressive Wirksamkeit eines hochdosierten *Hypericum*-Extrakts. *Münchener Medizinische Wochenschrift* 138, 29-33, 1996

Hänsgen, KD, Vesper, J, Ploch, M, Multicenter double-blind study examining the antidepressant effectiveness of the *Hypericum* extract LI 160. *J Geriatr Psychiatr Neurol* 7, 15-18. 1994

Harrer, G, Hübner WD, Podzuweit H, Effectiveness and tolerance of the *Hypericum* extract LI 160 compared to maprotiline: a multicenter double-blind study. *J Geriatr Psychiatr Neurol* 7, 24-28. 1994

Harrer, G., Sohmidt, K., Kuhn, K., Biller, A., Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. *Arzneim-Forsch/Drug Res.* 49, 289-296. 1999

He, YY., Chignell, CF., Miller, DS., Andley, UP., Roberts, JE. Phototoxicity in human lens epithelial cells promoted by St. John's Wort. *Photochem Photobiol.* 80, 583-586. 2004

Heinrich, M., Barnes, J., Gibbons, S., Williamson, E. *Fundamentals of Pharmacognosy and Phytotherapie.* Elsevier Science Limited, 2004

Henderson, L., Yue, Q.Y., Bergquist, C., Gerden, B., Arlett, P. St John's wort (*Hypericum perforatum*): Drug interactions and clinical outcomes. *Br J Clin Pharmacol.* 54, 349-356. 2002

Hicks, SM., Walker, AF., Gallagher, J., Middleton, RW., Wright, J. The significance of "nonsignificance" in randomized controlled studies: a discussion inspired by a double-blinded study on St. John's wort (*Hypericum perforatum* L.) for premenstrual symptoms. *J Altern Complement Med.* 10, 925-932. 2004

- Hoffmann, J., Kühl, ED. Therapie von depressiven Zuständen mit *Hypericum*. Ztschr Allgmed. 55, 776-782. 1979
- Hubner, WD., Kirste, T. Experience with St John's Wort (*Hypericum perforatum*) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res. 15, 367-370. 2001
- Hunt, EJ., Lester, CE., Lester, EA., Tackett, RL. Effect of St. John's wort on free radical production. Life Sci. 69, 181-190. 2001
- Hypericum* Depression Trial Study Group. Effect of *Hypericum perforatum* (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 287, 1807-1814. 2002
- Imai, H., Kotegawa, T., Tsutsumi, K., Morimoto, T., Eshima, N., Nakan, S., Ohashi, K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol 65, 701-707. 2008
- Irion, H. Drogen-Lexikon. Springer Verlag, Berlin/Göttingen/Heidelberg, 1955
- Ivetic, V., Popovic, M., Mimica-Dukic, N., Barak, O., Pilija, V. St. John's wort (*Hypericum perforatum* L.) and kindling epilepsy in rabbit. Phytomedicine. 9, 496-499. 2002
- Izzo, AA. Drug interactions with St. John's Wort (*Hypericum perforatum*): a review of the clinical evidence. Int J Clin Pharmacol Ther. 42, 139-148. 2004
- Jang, MH., Lee, TH, Shin, MC., Bahn, GH., Kim, JW., Shin, DH., Kim, EH., Kim, CJ. Protective effect of *Hypericum perforatum* Linn (St. John's wort) against hydrogen peroxide-induced apoptosis on human neuroblastoma cells. Neurosci Lett. 329. 177-180. 2002
- Johne, A., Perloff, ES., Bauer, S., Schmider, J., Mai, I., Brockmoller, J., Roots, I. Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin Pharmacol. 60, 617-622. 2004
- Juergenliemk, G., Boje, K., Huewel, S., Lohmann, C., Galla, HJ., Nahrstedt, A. *In vitro* studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. Planta Med. 69, 1013-1017. 2003
- Kalb, R., Trautmann-Sponsel, RD., Kieser, M. Efficacy and tolerability of *Hypericum* extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry. 34, 96-103. 2001
- Kaltschmidt, B., Heinrich, M., Kaltschmidt, C. Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells. Neuromolecular Med. 2, 299-309. 2002
- Kamuhabwa, AR., Augustijns, P., de Witte, PA. *In vitro* transport and uptake of protohypericin and hypericin in the Caco-2 model. Int J Pharm. 188, 81-86. 1999
- Karalpillai, D.,C., Bellomo, R. Convulsions associated with an overdose of St. John's wort. Med J Austr 186(4), 213-214. 2007
- Karsten, Weber, Fischer. Lehrbuch der Pharmakognosie. Gustav Fischer Verlag, Stuttgart, 1962

- Kasper, S., Anghelescu, IG., Szegedi, A., Dienel, A., Kieser, M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial. *BMC Med.* 4, 14. 2006
- Kasper, S., Volz, H.P., Moller, H.J., Dienel, A. Kieser, M. Continuation and long-term maintenance treatment with *Hypericum* extract WS 5570 after recovery from an acute episode of moderate depression – A double-blind, randomized, placebo controlled long-term trial. *Eur Neuropsychopharmacol* Aug 9. 2008
- Khalifa, AE. *Hypericum perforatum* as a nootropic drug: enhancement of retrieval memory of a passive avoidance conditioning paradigm in mice. *J Ethnopharmacol.* 76, 49-57. 2001
- Kientsch, U., Burgi, S., Ruedeberg, C., Probst, S., Honegger, UE. St. John's wort extract Ze 117 (*Hypericum perforatum*) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces 3-adrenoceptor numbers on cultured rat brain cells. *Pharmacopsychiatry.* 34, Suppl 1, 56-60. 2001
- Klier, CM., Schmid-Siegel, B., Schafer, MR., Lenz, G., Saria, A., Lee, A., Zernig, G. St. John's wort (*Hypericum perforatum*) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants. *J Clin Psychiatry.* 67, 305-309. 2006
- Klusa, V., Germane, S., Noldner, M., Chatterjee, SS. *Hypericum* extract and hyperforin: memory-enhancing properties in rodents. *Pharmacopsychiatry.* 34, 61-69. 2001
- Kumar, V., Jaiswal, AK., Singh, PN., Bhattacharya, SK. Anxiolytic activity of Indian *Hypericum perforatum* Linn: an experimental study. *Indian J Exp Biol.* 38, 36-41. 2000
- Kumar, V., Khanna, VK., Seth, PK., Singh, PN., Bhattacharya, SK. Brain neurotransmitter receptor binding and nootropic studies on Indian *Hypericum perforatum* Linn. *Phytother Res.* 16, 210-216. 2002
- Kumar, V., Singh, PN., Muruganandam, AV., Bhattacharya, SK. Effect of Indian *Hypericum perforatum* Linn on animal models of cognitive dysfunction. *J Ethnopharmacol.* 72, 119-128. 2000
- Laakmann, G., Jahn, G., Schule, C. *Hypericum perforatum* extract in treatment of mild to moderate depression. Clinical and pharmacological aspects. *Nervenarzt.* 73, 600-612. 2002
- Laakmann, G., Schule, C., Baghai, T., Kieser, M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. *Pharmacopsychiatry.* 31, 54-59. 1998
- Laggner, H., Schreier, S., Hermann, M., Exner, M., Muhl, A., Gmeiner, BM., Kapiotis, S. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug? *Free Radic Res.* 41, 234-241. 2007
- Länger, R., Kubelka, W., Phytokodex. Krause & Pachernegg GmbH, Gablitz, 2001
- Lavie, G., Mazur, Y., Lavie, D., Meruelo, D. The chemical and biological properties of hypericin – a compound with a broad spectrum of biological activities. *Med Res Rev* 15, 111-119. 1995
- Lecrubier, Y., Clerc, G., Didi, R. Kieser, M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. *Am J Psychiatry.* 159, 1361-1366. 2002
- Lenoir, S., Degenring, FH., Saller, R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of *Hypericum perforatum* L. *Phytomedicine.* 6, 141-146. 1999



- Leuschner, J. Preclinical toxicological profile of *Hypericum* extract LI 160. Abstracts of the 2<sup>nd</sup> International Conference on Phytomedicine, Munich. SL 80, 1996
- Linde, K., Berner, M., Egger, M., Mulrow, C. St John's wort for depression: meta-analysis of randomised controlled trials. *Br J Psychiatry*. 186, 99-107. 2005
- Linde, K. Johanniskraut bei Depression – eine Übersicht der randomisierten Studien bezogen auf einzelne Extrakte. [http://www.phytotherapie-komitee.de/Forschung/kfn\\_hyperic\\_281206.pdf](http://www.phytotherapie-komitee.de/Forschung/kfn_hyperic_281206.pdf), 2007
- List, PH., Hörhammer, L. Hager`s Handbuch der pharmazeutischen Praxis. Springer Verlag, Berlin/Heidelberg, 1976
- Lu, YH., Du, CB., Liu, JW., Hong, W., Wei, DZ. Neuroprotective effects of *Hypericum perforatum* on trauma induced by hydrogen peroxide in PC12 cells. *Am J Chin Med*. 32, 397-405. 2004
- Madabushi, R., Frank, B., Drewelow, B., Derendorf, H., Butterweck, V. Hyperforin in St. John's wort drug interactions. *Eur J Clin Pharmacol*. 62, 225-233. 2006
- Madaus, G. Lehrbuch der biologischen Heilmittel. Band II. Georg Thieme Verlag, Leipzig, 1938
- Maisenbacher, P., Kovar, KA. Analysis and stability of *Hyperici oleum*. *Planta Med*. 58, 351-354. 1992
- Mannel, M. Drug interactions with St John's wort : mechanisms and clinical implications. *Drug Saf*. 27, 773-797. 2004
- Mannucci, C., Pieratti, A., Firenzuoli, F., Caputi, AP., Calapai, G. Serotonin mediates beneficial effects of *Hypericum perforatum* on nicotine withdrawal signs. *Phytomedicine*. 14, 645-651.2007
- Martindale. The complete drug references. Pharmaceutical Press, London, 2002
- Meier, B. Vergleichbarkeit von Phytopharmaka am Beispiel von Johanniskraut. In: Loew, D., Blume, H., Dingermann Th. *Phytopharmaka V*, Steinkopff, Darmstadt, 1999
- Mills, E., Montori, VM., Wu, P., Gallicano, K., Clarke, M., Guyatt, G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. *BMJ*. 329, 23-30. 2004
- Misane, I., Ogren, SO. Effects of *Hypericum perforatum* (St. John's wort) on passive avoidance in the rat: evaluation of potential neurochemical mechanisms underlying its antidepressant activity. *Pharmacopsychiatry*. 34, Suppl 1, 89-97. 2001
- Mohanasundari, M., Sabesan, M. Modulating effect of *Hypericum perforatum* extract on astrocytes in MPTP induced Parkinson's disease in mice. *Eur Rev Med Pharmacol Sci*. 11, 17-20. 2007
- Mohanasundari, M., Srinivasan, MS., Sethuopathy, S., Sabesan, M. Enhanced neuroprotective effect by combination of bromocriptine and *Hypericum perforatum* extract against MPTP-induced neurotoxicity in mice. *J Neurol Sci*. 249, 140-144. 2006
- Montgomery, SA., Hübner, WD., Grigoleit, HG. Efficacy and tolerability of St. John´s wort extract compared with placebo in patients with mild to moderate depressive disorder. *Phytomedicine*. 7, Suppl 2, 107. 2000

- Moreno, RA., Teng, CT., Almeida, KM., Tavares Junior, H. *Hypericum perforatum* versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. *Rev Bras Psiquiatr.* 28, 29-32. 2006
- Mueller, SC., Majcher-Peszynska, J., Uehleke, B., Klammt, S., Mundkowski, RG., Miekisch, W., Sievens, H., Bauer, S., Frank, B., Kundt, G., Drewelow, B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. *Eur J Clin Pharmacol.* 62, 29-36. 2006
- Muller, T., Mannel, M., Murck, H., Rahlfs, VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. *Psychosom Med.* 66, 538-547. 2004
- Müller, WE., Rolli, M., Schäfer, C., Hafner, U. Effects of *Hypericum* extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopsychiatry.* 30, Suppl 2, 102-107. 1997
- Müller, W.E., Singer, A., Wonnemann, M, Hafner, U. Rolli, M., Schäfer, C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of *Hypericum* extract. *Pharmacopsychiatry* 31, Suppl.. 16-21. 1998
- Murck, H., Fava, M., Alpert, J., Nierenberg, AA., Mischoulon, D., Otto, MW., Zajecka, J., Mannel, M., Rosenbaum, JF. *Hypericum* extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of *Hypericum* extract, fluoxetine, and placebo. *Int J Neuropsychopharmacol.* 8, 215-221.2005
- Murck, H., Spitznagel, H., Ploch, M., Seibel, K., Schaffler, K. *Hypericum* extract reverses S-ketamine-induced changes in auditory evoked potentials in humans - possible implications for the treatment of schizophrenia. *Biol Psychiatry.* 59, 440-445. 2006
- Nöldner, M., Schötz, K. Rutin is essential for the antidepressant activity of *Hypericum perforatum* extracts in the forced swimming test. *Planta Med.* 68, 577-580. 2002
- Okpanyi, SN., Lizba, H., Scholl, BC., Miltenburger, HG. Genotoxicity of a standardized *Hypericum* extract. *Arzneimittelforschung.* 40, 851-855. 1990
- Ondrizek, RR., Chan, PJ., Patton, WC., King, A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. *Fertil Steril.* 71, 517-522. 1999
- Ozturk, N., Korkmaz, S., Ozturk Y. Wound-healing activity of St. John's Wort (*Hypericum perforatum* L.) on chicken embryonic fibroblasts. *J Ethnopharmacol.* 111, 33-39. 2006
- Pal, D., Mitra, AK. MDR- and CYP3A4-mediated drug-herbal interactions. *Life Sci.* 78, 2131-2145. 2006
- Panossian, A.G., Gabrielian, E., Manvelian, V., Jurcic, K., Wagner, H. Immunosuppressive effects of hypericin on stimulated human leukocytes: inhibition of the arachidonic acid release, leukotriene B<sub>4</sub> and interleukin-1 $\alpha$  production and activation of nitric oxide formation. *Phytomed.* 3, 19-28. 1996
- Paulke, A., Nöldner, M., Schubert-Zsilavec, M., Wurglics, M. St. John's wort flavonoids and their metabolites show antidepressant activity and accumulate in brain after multiple oral dose. *Pharmazie* 63, 296-302. 2008
- Perfumi, M., Ciccocioppo, R., Angeletti, S., Cucculelli, M. Massi, M. Effects of *Hypericum perforatum* extraction on alcohol intake in Marchigian Sardinian alcohol-preferring rats. *Alcohol Alcohol.* 34, 690-698. 1999

Perfumi, M., Mattioli, L., Cucculetti, M., Massi, M. Reduction of ethanol intake by chronic treatment with *Hypericum perforatum*, alone or combined with naltrexone in rats. *J Psychopharmacol.* 19, 448-454. 2005

Perfumi, M., Mattioli, L., Forti, L., Massi, M., Ciccocioppo, R. Effect of *Hypericum perforatum* CO<sub>2</sub> extract on the motivational properties (Wirksamkeit) of ethanol in alcohol-preferring rats. *Alcohol Alcohol.* 40, 291-296. 2005

Perfumi, M., Panocka, I., Ciccocioppo, R., Vitali, D., Frolidi, R., Massi, M. Effects of a methanolic extract and a hyperforin-enriched CO<sub>2</sub> extract of *Hypericum perforatum* on alcohol intake in rats. *Alcohol Alcohol.* 36, 199-206. 2001

Perfumi, M., Santoni, M., Cippitelli, A., Ciccocioppo, R., Frolidi, R., Massi, M. *Hypericum perforatum* CO<sub>2</sub> extract and opioid receptor antagonists act synergistically to reduce ethanol intake in alcohol-preferring rats. *Alcohol Clin Exp Res.* 27, 1554-1562. 2003

Philipp, M., Kohnen, R., Hiller, KO. *Hypericum* extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. *BMJ.* 319,1534-1538. 1999

Poginsky, B., Westendorf, J., Prosenc, N., Kuppe, M., Marquardt, H. *Dtsch Apoth Ztg.* 128, 1364-1366. 1988

Randlov, C., Mehlsen, J., Thomsen, CF., Hedman, C., von Fircks, H., Winther, K. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia-a double-blind placebo-controlled study. *Phytomedicine.* 13, 215-221. 2006

Rayburn, WF., Gonzalez, CL., Christensen, HD., Harkins, TL., Kupiec, TC. Impact of *Hypericum* (St.-John's-wort) given prenatally on cognition of mice offspring. *Neurotoxicol Teratol.* 23, 629-637. 2001

Rezvani, AH., Overstreet, DH., Yang, Y., Clark, E. Jr. Attenuation of alcohol intake by extract of *Hypericum perforatum* (St. John's Wort) in two different strains of alcohol-preferring rats. *Alcohol Alcohol.* 34, 699-705. 1999

Roder, C., Schaefer, M., Leucht, S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's Wort. *Fortschr Neurol Psychiatr.* 72, 330-343. 2004

Rychlik, R., Siedentop, H., von den Driesch, V., Kasper, S. St. John's wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily. *Fortschr Med Orig.* 119, 119-128. 2001

Sanchesz-Reus, MI., Gomez del Rio MA., Iglesias, I., Elorza, M., Slowing, K., Benedi, J. Standardized *Hypericum perforatum* reduces oxidative stress and increases gene expression of antioxidant enzymes on rotenone-exposed rats. *Neuropharmacology.* 52, 606-616. 2007

Sattler, S., Schaefer, U., Schneider, W., Hoelzl, J., Lehr, CM. Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. *J Pharm Sci.* 86, 1120-1126. 1997

Schempp, CM., Ludtke R., Winghofer, B., Simon, JC. Effect of topical application of *Hypericum perforatum* extract (St. John's wort) on skin sensitivity to solar simulated radiation. *Photodermatol Photoimmunol Photomed.* 16, 125-128. 2000

Schempp, CM., Muller, K., Winghofer, B., Schulte-Monting, J., Simon, JC. Single-dose and steady-state administration of *Hypericum perforatum* extract (St John's Wort) does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation. Arch Dermatol. 137, 512-513. 2001

Schempp, CM., Simon-Haarhaus, B., Simon, JC. Phototoxic and apoptosis-inducing capacity of pseudohypericin. Planta Med. 68, 171-173. 2002

Schempp, CM., Windeck, T., Hezel, S., Simon, JC. Topical treatment of atopic dermatitis with St. John's wort cream-a randomized, placebo controlled, double blind half-side comparison. Phytomedicine. 10, 31-37. 2003

Schempp, CM., Winghofer, B., Langheinrich, M., Schopf, E., Simon, JC. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of *Hypericum perforatum* extract (St. John's wort). Skin Pharmacol Appl Skin Physiol. 12, 299-304. 1999

Schempp, CM., Winghofer, B., Ludtke, R., Simon-Haarhaus, B., Schopf, E., Simon, JC. Topical application of St John's wort (*Hypericum perforatum* L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br J Dermatol. 142, 979-984. 2000

Schempp, CM., Winghofer, B., Muller, K., Schulte-Monting, J., Mannel, M., Schopf, E., Simon, JC. Effect of oral administration of *Hypericum perforatum* extract (St. John's Wort) on skin erythema and pigmentation induced by UVB, UVA, visible light and solar simulated radiation. Phytother Res. 17, 141-146. 2003

Schey, KL., Patat, S., Chignell, CF., Datillo, M., Wang, RH., Roberts, JE. Photooxidation of lens alpha-crystallin by hypericin (active ingredient in St. John's Wort). Photochem Photobiol. 72, 200-203. 2000

Schimmer, O., Häfele, E., Krüger, A. The mutagenic potencies of plant extracts containing quercetin in Salmonella typhimurium TA98 and TA100. Mutat Res. 206, 201-208. 1988

Schmitt, LA., Liu, Y., Murphy, PA., Birt, DF. Evaluation of the light-sensitive cytotoxicity of *Hypericum perforatum* extracts, fractions, and pure compounds. J Agric Food Chem. 54, 2881-2890. 2006

Schmitt, LA., Liu, Y., Murphy, PA., Petrich, JW., Dixon, PM., Birt, DF. Reduction in hypericin-induced phototoxicity by *Hypericum perforatum* extracts and pure compounds. J Photochem Photobiol B. 85, 118-130. 2006

Schneider, G. Arzneidrogen, Wissenschaftsverlag, Mannheim, 1990

Schrader, E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 15, 61-68. 2000

Schrader, E., Meier, B., Brattström, A. *Hypericum* treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Human Psychopharmacology. 13, 163-169. 1998

Schulz, HU., Schurer, M., Bassler, D., Weiser, D. Investigation of the effect on photosensitivity following multiple oral dosing of two different *Hypericum* extracts in healthy men. Arzneimittelforschung. 56, 212-221. 2006

Schulz, V., Schurer, M., Bassler, B., Weiser, D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and

multiple oral dose studies with a *Hypericum* extract containing tablet in healthy male volunteers. *Arzneimittelforschung*. 55, 561-568. 2005

Shelton, RC., Keller, MB., Gelenberg, A., Dunner, DL., Herschfeld, R., Thase, ME., Russell, J., Lydiard, RB., Crits-Cristoph, P., Gallop, R., Todd, L., Hellerstein, D., Goodnick, P., Keitner, G., Stahl, SM., Halbreich, U. Effectiveness of St John's wort in major depression: a randomized controlled trial. *JAMA*. 285, 1978-1986. 2001

Siepmann, M., Kirch, W., Krause, S., Joraschky, P., Muek-Weymann, M. The effects of St. John's wort extract and amitriptyline on autonomic responses of blood vessels and sweat glands in healthy volunteers. *J Clin Psychopharmacol*. 24, 79-82. 2004

Siepmann, M., Krause, S., Joraschky, P., Muck-Weymann, M., Kirch, W. The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men. *Br J Pharmacol*. 54, 272-282. 2002

Silva, BA., Dias, AC., Ferreres, F., Malva, JO., Oliveira, CR. Neuroprotective effect of *H. perforatum* extracts on beta-amyloid-induced neurotoxicity. *Neurotox Res*. 6, 119-130. 2004

Simbrey, K., Winterhoff, H., Butterweck, V. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex. *Life Sci*. 74, 1027-1038. 2004

Simmen, U., Schweitzer, C., Burkard, W., Schaffner, W., Lundstrom, K. *Hypericum perforatum* inhibits the binding of  $\mu$ - and  $\kappa$ -opioid receptor expressed with the Semliki Forest virus system. *Pharm Acta Helv* 73, 53-56. 1998

Sommer, H., Harrer, G. Placebo-controlled double-blind study examining the effectiveness of an *Hypericum* preparation in 105 mildly depressed patients. *J Geriatr Psychiatr Neurol* 7, 9-11. 1994

Sosa, S., Pace, R., Bornancin, A., Morazzoni, P., Riva, A., Tubaro, A., Della Loggia, R. Topical anti-inflammatory activity of extracts and compounds from *Hypericum perforatum* L. *J Pharm Pharmacol*. 59, 703-709. 2007

Spiess, PE., Grossmann, HB. Fluorescence cystoscopy: is it ready for use in routine clinical practice? *Curr Opin Urol*. 16, 372-376. 2006

Stevinson, C., Ernst, E. A pilot study of *Hypericum perforatum* for the treatment of premenstrual syndrome. *BJOG*. 107, 870-876. 2000

Stevinson, C., Ernst, E. Can St. John's wort trigger psychoses? *Int J Clin Pharmacol Ther*. 42, 473-480. 2004

Swiss Pharmacopoeia (Pharm. Helv. 8). Eidgenössisches Department des Inneren, Bern, 1999

Szegedi, A., Kohlen, R., Dienel, A., Kieser, M. Acute treatment of moderate to severe depression with *Hypericum* extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. *BMJ*. 330, 503-506. 2005

Teufel-Mayer, R., Gleitz, J. Effects of long-term administration of *Hypericum* extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. *Pharmacopsychiatry*. 30, Suppl 2, 113-113. 1997

- Thiede, HM., Walper, A. Inhibition of MAO and COMT by *Hypericum* extracts and hypericin. J Geriatr Psychiatry Neurol. 7, Suppl 1, 54-56. 1994
- Traynor, NJ., Beattie, PE., Ibbotson, SH., Moseley, H., Ferguson, J., Woods, JA. Photogenotoxicity of hypericin in HaCaT keratinocytes: implications(Auswirkung) for St. John's Wort supplements and high dose UVA-1 therapy. Toxicol Lett. 158, 220-224. 2005
- Trofimiuk, E., Walesiuk, A., Braszko, JJ. St john's wort (*Hypericum perforatum*) counteracts deleterious effects of the chronic restraint stress on recall in rats. Acta Neurobiol Exp. 66, 129-138. 2006
- Trofimiuk, E., Walesiuk, A., Braszko, JJ. St John's wort (*Hypericum perforatum*) diminishes cognitive impairment caused by the chronic restraint stress in rats. Pharmacol Res. 51, 239-246. 2005
- Uebelhack, R., Gruenwald, J., Graubaum, HJ., Busch, R. Efficacy and tolerability of *Hypericum* extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther. 21, 265-275. 2004
- Upton, R. St. John's Wort, Monograph of the American Herbal Pharmacopoeia, 1997
- Usai. M., Leggio. B., Grappi. S., Nanni. G., Gambarana. C., Tolu. P., Giachetti. D., De Mortis. MG. *Hypericum perforatum* subspecies angustifolium shows a protective activity on the consequences of unavoidable stress exposure at lower doses than *Hypericum perforatum* perforatum. Pharmacopsychiatry. 36, 283-287. 2003
- Uzbay, T.I. *Hypericum perforatum* and substance dependence: A review. Phytother Res 22, 578-582. 2008
- Van Gorp, G., Meterissian, GB., Haiek, LN., McCusker, J., Bellavance, F. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician. 48, 905-912. 2002
- Volz, HP., Murck, H., Kasper, S., Moller, HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology. 164, 294-300. 2002
- Vorbach. EU., Arnoldt. KH., Hubner. WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 30, Suppl 2, 81-85. 1997
- Volz. HP., Laux. P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr Pschiatry. 4, Suppl 1, 133-137. 2000
- Wagner, H., Bauer, R. Arzneidrogen und ihre Inhaltsstoffe. Band 2. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1999
- Wahlman, J., Hirst, M., Roberts, JE., Prickett, CD., Trevithick, JR. Focal length variability and protein leakage as tools for measuring photooxidative damage to the lens. Photochem Photobiol. 78, 88-92. 2003
- Weber, W., Van der Stoep, A., McCarty, R.L., Weiss, N.S., Biederman, J., McClellan, J. *Hypericum perforatum* (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents. JAMA 299, 2633-2641. 2008
- Wenk, M., Todesco, L., Krahenbuhl, S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 57, 495-499. 2004

- Werneke, U., Horn, O., Taylor, DM. How effective is St John's wort? The evidence revisited. *J Clin Psychiatry*. 65, 611-617. 2004
- Wheatley, D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients--a controlled 6-week clinical trial. *Pharmacopsychiatry*. 30, Suppl 2, 77-80. 1997
- Whitten, DL., Myers, SP., Hawrelak, JA., Wohlmuth, H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. *Br J Clin Pharmacol*. 62, 512-526. 2006
- WHO monographs. WHO-Monographs on selected medical plants. World Health Organization, Geneva, 2002
- Wichtl, M. Teedrogen. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1984
- Wichtl, M. Teedrogen. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 4. Auflage 2002
- Wichtl, M. Herbal Drugs and Phytopharmaceuticals. Medpharm scientific publishers, Stuttgart 2004
- Widy-Tyszkiewicz, E., Piechal, A., Joniec, I., Blecharz-Klin, K. Long term administration of *Hypericum perforatum* improves spatial learning and memory in the water maze. *Biol Pharm Bull*. 25, 1289-1294. 2002
- Wielgus, AR., Chignell, CF., Miller, DS., Van Houten, B., Meyer, J., Hu, DN., Roberts, JE. Phototoxicity in Human Retinal Epithelial Cells Promoted by Hypericin, a Component of St. John's Wort. *Photochem Photobiol*. 83, 706-713 2006
- Wilhelm, KP., Biel, S., Siegers, CP. Role of flavonoids in controlling the phototoxicity of *Hypericum perforatum* extracts. *Phytomedicine*. 8, 306-309. 2001
- Woelk, H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. *BMJ*. 321, 536-539. 2000
- Wright, CW., Gott, M., Grayson, B., Hanna, M., Smith, AG., Sunter, A., Neill, JC. Correlation of hyperforin content of *Hypericum perforatum* (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study. *J Psychopharmacol*. 17, 403-408. 2003
- Wurglics, M., Schubert-Zsilavecz, M. *Hypericum perforatum*: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. *Clin Pharmacokinet*. 45, 449-468. 2006
- Zhou, S., Chan, E., Pan, SQ., Huang, M., Lee, EJ. Pharmacokinetic interactions of drugs with St John's wort. *J Psychopharmacol*. 18, 262-276. 2004
- Zörnig, H. Arzneidrogen. Teil II. Verlag Klinkhardt, Leipzig, 1911
- Zou, Y, Lu, Y., Wei, D. Antioxidant activity of a flavonoid-rich extract of *Hypericum perforatum* L. *in vitro*. *J Agric Food Chem*. 52, 5032-5039. 2004
- Zou, Y., Lu, Y., Wei, D. Hypocholesterolemic effects of a flavonoid-rich extract of *Hypericum perforatum* L. in rats fed a cholesterol-rich diet. *J Agric Food Chem*. 53, 2462-2466. 2005